Diminishing impact of preoperative carcinoembryonic antigen (CEA) in prognosis of Dukes' C colorectal cancer

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1933-1941

  Katoh, Hiroshi ^a   Yamashita, Keishi ^a   Kokuba, Yukihito ^a   Satoh, Takeo ^a   Ozawa, Heita ^a   Hatate, Kazuhiko ^a   Ihara, Atsushi ^a   Nakamura, Takatoshi ^a   Onozato, Wataru ^a   Watanabe, Masahiko ^a,b  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

CEA; Colorectal cancer; Dukes' C; Prognosis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROTEOGLYCANS; TREATMENT OUTCOME;

EID: 45949093678     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Cunningham D and Starling N: Adjuvant chemotherapy of colorectal cancer. Lancet 370: 1980-1981, 2007.
3. Douillard JY, Cunningham D, Roth A D, Navarro M, James R D, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
4. Douillard JY, Tilleul P, Ychou M, Dufour P, Perrocheau G, Seitz JF, Maes P, Lafuma A and Husseini F: Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology 72: 248-254, 2008.
5. Fietkau R and Klautke G: Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer: the type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients. J Clin Oncol 26: 507-508; author reply 508-509, 2008.
6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
7. Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH and Kim H: Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 30: 637-643, 2007.
8. Posner MC, Niedzwiecki D, Venook A P, Hollis DR, Kindler H L, Martin EW, Schilsky RL and Goldberg RM: A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol 15: 158-164, 2008.
9. Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T and Piedbois P: Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22: 484-492, 2004.
10. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
11. Harrison LE, Guillem JG, Paty P and Cohen AM: Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 185: 55-59, 1997.
12. Marchena J, Acosta MA, Garcia-Anguiano F, Simpson H and Cruz F: Use of the preoperative levels of CEA in patients with colorectal cancer. Hepatogastroenterology 50: 1017-1020, 2003.
13. Scott NA, Wieand HS, Moertel CG, Cha SS, Beart RW and Lieber MM: Colorectal cancer. Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 122: 1375-1379, 1987.
14. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK and Oettgen HF: Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299: 448-451, 1978.
15. Weissenberger C, Von Plehn G, Otto F, Barke A, Momm F and Geissler M: Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9. Anticancer Res 25: 1787-1793, 2005.
16. Wiggers T, Arends JW and Volovics A: Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 31: 33-41, 1988.
17. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS and Chang SC: Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 124: 169-174, 2005.
18. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 47: 624-630, 2001.
19. Jessup JM, Stewart A, Greene FL and Minsky BD: Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294: 2703-2711, 2005.
20. Japanese Society for Cancer of the Colon and Rectum (edited): General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (7th Edition), Tokyo, Kanehara&Co Ltd, 2006.
21. Weitz J, D'Angelica M, Gonen M, Klimstra D, Coit DG, Brennan MF and Karpeh MS: Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. J Clin Oncol 21: 4597-4603, 2003.
22. Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N and Watanabe M: Surgical resection of stage IV gastric cancer and prognosis. Anticancer Res 27: 4381-4386, 2007.
23. Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N and Watanabe M: Transfusion alert for patients with curable cancer. World J Surg 31: 2315-2322, 2007.
24. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc 53: 457-481, 1958.
25. Cox D: Regression models and life-tables. J R Stat Soc (B) 34: 187-220, 1972.
26. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB and Boland CR: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123-131, 1999.
27. Ribic CM, Sargent D J, Moore MJ, Thibodeau SN, French AJ, Goldberg R M, Hamilton S R, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M and Gallinger S: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003.
28. O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425 2004.